CEO Alan Shortall of Unilife reports that the Company held its Annual General Meeting in New York City in December 2011. In addition to Alan Shortall, Unilife also had in attendance its full Board of Directors and senior management to meet with stockholders and analysts. The meeting, says Alan Shortall, served as an opportunity to review some of the achievements that has brought the emerging global leader for advanced drug delivery systems to its current position of strength.
Alan Shortall said Unilife continued this year to deliver on its key business milestones.
“In December 2010, Unilife opened its new state-of-the-art facility in York, Pennsylvania just under a year ago. This modern center for device innovation, which is the size of three football fields, is a key enabler for the business of Unilife,” says Alan Shortall.
According to Alan Shortall, “Whenever a pharmaceutical company, shareholder or business partner comes to visit our facility, they immediately recognize the unique value proposition of Unilife. The operational capabilities and industry expertise that we have brought together in York, PA make a compelling choice to serve the device innovation needs of pharmaceutical and biotechnology companies,” adds Alan Shortall.
Unilife now employs more than 140 people at York, PA, as well as other device innovation centers within the State.
Key operational activities that take place every day at the York facility, reports Alan Shortall, include product development, rapid prototyping, pilot and commercial production, bio-analytical testing, packaging, quality assurance and supply chain management. “In many ways,” says Alan Shortall, “we serve as a one stop shop for device innovation.”
Unilife has changed the rules of competition to better serve the needs of pharmaceutical companies. As a result, notes Alan Shortall, “we have been flooded with job applications this year from high-caliber industry leaders wanting to join our team. Unilife has selected the best of the best, all of which fit into our entrepreneurial culture and have the expertise and energy to move fast,” continues Alan Shortall.
“Unilife had several key business milestones for the 2011 fiscal year. One major one was the successful completion of the industrialization program for the Unifill syringe. We hit every one of our ten quarterly milestones, from the start of the program in 2008 to its completion, six months ahead of schedule, in July. We are very committed to hitting our milestones at Unilife.” Alan Shortall said Unilife’s commercial plans for the Unifill syringe remained right on track.
Alan Shortall reports that Unilife has received very strong levels of acceptance for the Unifill syringe from customers, healthcare workers and patients. “We are now working very closely with many top names in the pharmaceutical industry that view the Unifill syringe as a game-changer, states Alan Shortall. “Unilife has a number of significant opportunities for the Unifill syringe that are now advancing in the commercial pipeline at Unilife.”
Alan Shortall says that these opportunities included pipeline and approved drugs targeted for use across a number of therapeutic drug classes, and adds that Unilife is now collaborating with many pharmaceutical companies to address their unmet needs for drug delivery.
For more information, Alan Shortall can be contacted at Unilife by email at email@example.com or online at www.unilife.com.